Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B9e1d4cc38e083df7a8d49b715f79c0d6> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B9e1d4cc38e083df7a8d49b715f79c0d6 NCIT_P378 "NCI" @default.
- B9e1d4cc38e083df7a8d49b715f79c0d6 type Axiom @default.
- B9e1d4cc38e083df7a8d49b715f79c0d6 annotatedProperty IAO_0000115 @default.
- B9e1d4cc38e083df7a8d49b715f79c0d6 annotatedSource NCIT_C116844 @default.
- B9e1d4cc38e083df7a8d49b715f79c0d6 annotatedTarget "An orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, fenebrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways, which leads to the inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B-lymphocyte development, activation, signaling, proliferation and survival." @default.